skip to main content

Diabetes Mellitus — UKMLA MCQ

Instant feedback + full explanation. One question, done properly.

HardDiabetes Management in Older AdultsDiabetes MellitusUKMLAMRCGP AKTMRCP Part 1

A 15-year-old weighing 46 kg has PNH and has remained clinically stable during seven months of ravulizumab. Crovalimab is otherwise suitable. Which statement best reflects its current NICE position?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Crovalimab is suitable after six stable months of C5 inhibition

The best answer is “Crovalimab is suitable after six stable months of C5 inhibition”. TA1019 covers people aged at least 12 who weigh at least 40 kg and either have symptomatic high-activity haemolysis or are clinically stable after at least six months of a C5 inhibitor. This patient meets the age, weight and switch criteria. Crovalimab replaces rather than accompanies another C5 inhibitor.

Reference: NICE TA1019, Crovalimab for paroxysmal nocturnal haemoglobinuria: https://www.nice.org.uk/guidance/ta1019/chapter/1-Recommendations